会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Liquid, aqueous pharmaceutical composition of Factor VII polypeptides
    • 因子VII多肽的液体,水性药物组合物
    • US20060166882A1
    • 2006-07-27
    • US11304427
    • 2005-12-15
    • Michael JensenBirthe HansenTroels KornfeltKirsten Jakobsen
    • Michael JensenBirthe HansenTroels KornfeltKirsten Jakobsen
    • A61K38/36A61K33/34A61K33/26
    • A61K33/24A61K9/0019A61K33/26A61K33/32A61K33/34A61K38/4846A61K45/06A61K47/02A61K47/10A61K47/183A61K2300/00
    • The present invention is directed to liquid, aqueous pharmaceutical compositions containing Factor VII polypeptides, and methods for preparing and using such compositions, as well as vials containing such compositions, and the use of such compositions in the treatment of a Factor VII-responsive syndrome, e.g., bleeding disorders, including those caused by clotting Factor deficiencies (e.g. haemophilia A, haemophilia B, coagulation Factor VII deficiency); by thrombocytopenia or von Willebrand's disease, or by clotting Factor inhibitors, and intra cerebral haemorrhage, or excessive bleeding from any cause. The preparations may also be administered to patients in association with surgery or other trauma or to patients receiving anticoagulant therapy. More particularly, the invention relates to liquid compositions stabilised against chemical and/or physical degradation. The main embodiment is represented by a liquid, aqueous pharmaceutical composition comprising a Factor VII polypeptide (i); a buffering agent (ii) suitable for keeping pH in the range of from about 4.0 to about 9.0; at least one metal-containing agent (iii), wherein said metal is selected from the group consisting of first transition series metals of oxidation state +II, except zinc, such as chromium, manganese, iron, cobalt, nickel, and copper; and a non-ionic surfactant (iv).
    • 本发明涉及含有因子VII多肽的液体含水药物组合物,以及用于制备和使用这些组合物的方法以及含有这种组合物的小瓶,以及这些组合物在治疗因子VII应答综合征中的用途, 例如出血性疾病,包括由凝血因子缺乏引起的出血性疾病(如血友病A,血友病B,凝血因子VII缺乏症); 血小板减少症或维勒布兰氏病,或凝血因子抑制剂,脑内出血或任何原因引起的过度出血。 制剂也可以与外科手术或其他创伤相关的患者或接受抗凝治疗的患者给予。 更具体地说,本发明涉及防止化学和/或物理降解稳定的液体组合物。 主要实施方案由包含因子VII多肽(i)的液体,水性药物组合物表示; 适于将pH保持在约4.0至约9.0范围内的缓冲剂(ii); 至少一种含金属的试剂(iii),其中所述金属选自氧化态+ II的第一过渡系列金属,除了锌,如铬,锰,铁,钴,镍和铜之外; 和非离子表面活性剂(iv)。